Plain-English translation of NCT07412132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a medication originally used for epilepsy, can help reduce depression in people with bipolar disorder who haven't responded to standard treatments. You would take the medication (or a placebo) alongside your current bipolar medications for 12 weeks. Early research suggests this treatment may help ease both depression and anxiety symptoms.
Many people with bipolar disorder continue to struggle with severe depression even after trying two or more standard medications. This trial is exploring whether this new treatment could offer hope for those with hard-to-treat depression.
You likely qualify if…
You likely don't qualify if…
You would visit the study site regularly over 12 weeks while taking either the new medication or a placebo (fake pill), in addition to your current bipolar medications. The researchers will check on your depression symptoms, side effects, and overall well-being throughout the study. Neither you nor the research team will know whether you're receiving the actual medication or the placebo until the study ends.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Brazil